Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2Gastrointestinal 1

Conditions

Head and Neck Neoplasms 2Carcinoma, Squamous Cell 2Squamous Cell Carcinoma of Head and Neck 1Esophageal Squamous Cell Carcinoma 1Anus Neoplasms 1

Interventions

Cisplatin 258Radiotherapy 193Cetuximab 151pembrolizumab 123Docetaxel 97Fluorouracil 92Carboplatin 80Paclitaxel 78Radiotherapy, Intensity-Modulated 72Surveys and Questionnaires 46Nivolumab 42Drug Therapy 34Radiation 33Blood Specimen Collection 27Erlotinib Hydrochloride 26Gemcitabine 25Immunohistochemistry 22Gefitinib 22Cyclophosphamide 22Surgical Procedures, Operative 21Standard of Care 20durvalumab 19Pemetrexed 19Magnetic Resonance Spectroscopy 19Radiosurgery 17Capecitabine 17Chemotherapy, Adjuvant 16Celecoxib 16Biopsy 16atezolizumab 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Head and Neck Neoplasms × ON 01910 × Head & Neck × Clear all
NCT01807546 2017-06-26

Oral Rigosertib for Squamous Cell Carcinoma

Traws Pharma, Inc.

Phase 2 Completed
64 enrolled
GastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Anus Neoplasms, Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT02107235 2017-06-23

Platinum-based Chemoradiotherapy and Rigosertib in Head and Neck Cancer

Traws Pharma, Inc.

Phase 1 Completed
2 enrolled
Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡